Johanna Mercier Net Worth

The estimated Net Worth of Johanna Mercier is at least $20 Million dollars as of 10 September 2024. Ms. Mercier owns over 3,752 units of Gilead Sciences stock worth over $8,840,105 and over the last 5 years she sold GILD stock worth over $3,139,406. In addition, she makes $8,049,390 as Chief Commercial Officer at Gilead Sciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Mercier GILD stock SEC Form 4 insiders trading

Johanna has made over 21 trades of the Gilead Sciences stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 3,752 units of GILD stock worth $303,687 on 10 September 2024.

The largest trade she's ever made was selling 19,496 units of Gilead Sciences stock on 4 May 2021 worth over $1,288,491. On average, Johanna trades about 3,768 units every 46 days since 2019. As of 10 September 2024 she still owns at least 109,218 units of Gilead Sciences stock.

You can see the complete history of Ms. Mercier stock trades at the bottom of the page.

Johanna Mercier biography

Johanna Mercier serves as Chief Commercial Officer of the Company. Ms. Mercier leads Gilead’s Commercial organization with responsibility for commercializing Gilead’s therapies in countries and regions around the world. Prior to joining Gilead in July 2019, Ms. Mercier spent over 25 years at Bristol-Myers Squibb, where she was most recently President and Head of U.S., France, Germany, Japan, Korea and Taiwan. In her role, she oversaw a complex organization comprising a majority of the company’s business. Ms. Mercier was also actively engaged with the policy and advocacy community to ensure the affordability and access of prescription medicines to patients. Ms. Mercier began her career in sales and marketing in Canada, then went on to lead worldwide early and clinical portfolios, followed by market teams across both the U.S. and Europe. She was Bristol-Myers Squibb’s General Manager of UK & Ireland and later President of Worldwide Markets for Europe, Australia and Canada. In her most recent role, which included responsibility for the U.S. business and other priority markets, she successfully evolved the culture and drove strong commercial execution with double-digit growth and multiple launches that changed the standard of care in melanoma and renal cancers. Ms. Mercier holds a science degree from the University of Montreal and an MBA from Concordia University.

What is the salary of Johanna Mercier?

As the Chief Commercial Officer of Gilead Sciences, the total compensation of Johanna Mercier at Gilead Sciences is $8,049,390. There are 1 executives at Gilead Sciences getting paid more, with Daniel O'Day having the highest compensation of $29,107,900.

How old is Johanna Mercier?

Johanna Mercier is 50, she's been the Chief Commercial Officer of Gilead Sciences since 2019. There are 21 older and 2 younger executives at Gilead Sciences. The oldest executive at Gilead Sciences, Inc. is Richard Whitley, 74, who is the Independent Director.

What's Johanna Mercier's mailing address?

Johanna's mailing address filed with the SEC is GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY, CA, 94404.

Insiders trading at Gilead Sciences

Over the last 22 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger, and John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.

What does Gilead Sciences do?

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.

Complete history of Ms. Mercier stock trades at Gilead Sciences and Neurocrine Biosciences

Gilead Sciences executives and stock owners

Gilead Sciences executives and other stock owners filed with the SEC include:

• Daniel O'Day,
  Chairman of the Board, Chief Executive Officer
• Johanna Mercier,
  Chief Commercial Officer
• Daniel P. O'Day,
  Chairman & CEO
• Andrew Dickinson,
  Chief Financial Officer, Executive Vice President
• Brett Pletcher,
  Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
• Johanna Mercier,
  Chief Commercial Officer
• Dr. Merdad V. Parsey M.D., Ph.D.,
  Chief Medical Officer
• Merdad Parsey,
  Chief Medical Officer
• Brett A. Pletcher,
  Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
• Andrew D. Dickinson,
  Exec. VP & CFO
• Per Wold-Olsen,
  Independent Director
• Richard Whitley,
  Independent Director
• Kelly Kramer,
  Independent Director
• Kevin Lofton,
  Lead Independent Director
• Harish Manwani,
  Independent Director
• Jacqueline Barton,
  Independent Director
• Sandra Horning,
  Independent Director
• Anthony Welters,
  Director
• Javier Rodriguez,
  Director
• Michael Quigley,
  Senior Vice President - Research Biology
• Linda Higgins,
  Senior Vice President - Head of External Innovation
• Jyoti Mehra,
  Executive Vice President of Human Resources
• Dr. Linda Slanec Higgins Ph.D.,
  Sr. VP & Head of External Innovation
• Jyoti K. Mehra,
  Exec. VP of HR
• Deborah H. Telman,
  Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.
• Dr. Diana M. Brainard M.D.,
  Sr. VP of HIV & Emerging Viral Infections
• Dr. Taiyin Yang,
  Exec. VP of Pharmaceutical Devel. & Manufacturing
• Jacquie Ross C.F.A.,
  VP of Investor Relations
• Diane E. Wilfong,
  Sr. VP, Corp. Controller & Chief Accounting Officer
• John Francis Cogan,
  Director
• John W Madigan,
  Director
• Robin L Washington,
  SVP, CFO
• Norbert W Bischofberger,
  SVP, Research
• James R Meyers,
  SVP Comm Ops North America
• Nicholas G Moore,
  Director
• Gayle E Wilson,
  Director
• Kevin Young,
  EVP, Commercial Operations
• Laura Hamill,
  EVP, Worldwide Commercial Ops
• Carla A Hills,
  Director
• Etienne Davignon,
  Director
• Paul Rutherford Carter,
  EVP Commercial Ops
• John C Martin,
  President and CEO
• John F Milligan,
  EVP, Chief Financial Officer
• John G Mc Hutchison,
  Chief Scientific Off/HeadR&D
• James M Denny,
  Director
• Gordon Earle Moore,
  Director
• Kristen Metza,
  SVP, Human Resources
• Gregg H Alton,
  SVP, General Counsel
• Paul Berg,
  Director
• Louis G Lange,
  EVP Cardiovascular Therapeutic
• Taiyin Yang,
  SVP, Pharm Dev & Mfg
• William A Lee,
  SVP Research and PPD
• Anthony Caracciolo,
  SVP
• Caroline Dorsa,
  SVP, Chief Financial Officer
• John J Toole,
  SVP
• George P Shultz,
  Director
• Alan Bruce Montgomery,
  SVP, Respiratory Therapeutics
• Michael K Inouye,
  SVP
• Mark L Perry,
  EVP Operations
• Cordell W Hull,
  Director
• Diane E. Wilfong,
  SVP, Controller & CAO
• Sandra Patterson,
  SVP, Controllership
• Jeffrey Bluestone,
  Director
• Deborah H Telman,
  EVP, Corporate Affairs & GC
• Ted W Love,
  Director